Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-24	ILA 259.70	-1.59%	28,881
26-09-23	ILA 263.90	+3.17%	32,404
26-09-22	ILA 255.80	-3.00%	104,866
26-09-17	ILA 263.70	-0.19%	41,918

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - TEL AVIV STOCK EXCHANGE 10:24:13 2026-09-24 EDT			5-day change	1st Jan Change
259.70 ^ILa	-1.59%		-1.52%	-52.86%

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	78.73M 0 25.82M 22.66M 21.4M 19.5M 36.51M 2.48B 36.77M 256M 99.2M 1.26B 96.96M 94.86M 4.06B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	58.59M 0 19.22M 16.86M 15.93M 14.51M 27.17M 1.84B 27.36M 191M 73.82M 941M 72.16M 70.6M 3.02B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-23	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI

09-03	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program	PR
07-09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03-03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
03-02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news: Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Price Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-1.59%
1 week	-1.52%
Current month	-2.11%
1 month	+0.23%
3 months	-10.60%
6 months	-28.87%
Current year	-52.86%

1 week	251.1	275
1 month	250	316.1
Current year	212	853
1 year	212	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	54	2019-05-31
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	2019-05-31
Alon Sinai COO	Chief Operating Officer	59	2019-06-30

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	59	2019-06-30
Tal Dvir BRD	Director/Board Member	51	2019-05-31
Stanley Hirsch BRD	Director/Board Member	68	2022-07-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	-1.59%	-1.52%	-44.48%	-41.30%	25.82M
LONZA GROUP AG	-0.14%	+4.33%	+9.88%	+31.73%	47.97B
IQVIA HOLDINGS INC.	-1.69%	+1.48%	+53.02%	+33.59%	44.5B
REVOLUTION MEDICINES, INC.	+2.56%	+7.34%	+382.17%	+594.81%	43.93B
BEONE MEDICINES AG	+0.24%	+2.85%	+9.78%	+89.54%	41.03B
CELLTRION, INC.	-0.62%	-1.11%	+4.70%	+46.02%	29.85B
MEDPACE HOLDINGS, INC.	-0.28%	+1.07%	+26.83%	+152.91%	17.27B
EUROFINS SCIENTIFIC SE	-0.46%	+1.20%	+26.78%	+41.32%	15.3B
ASCENDIS PHARMA A/S	-2.21%	-4.70%	-	-	14.82B
TEMPUS AI, INC.	+3.37%	+9.21%	+9.93%	-	15.34B
Average	-0.08%	+1.96%	+53.18%	+118.58%	27B
Weighted average by Cap.	+0.11%	+2.86%	+83.02%	+156.19%

	2024	2025
Net sales	-	-
Net income	-15.58M -0 -5.11M -4.49M -4.24M -3.86M -7.23M -490M -7.28M -50.69M -19.63M -250M -19.19M -18.78M -804M	-27.82M -0 -9.13M -8.01M -7.56M -6.89M -12.9M -875M -12.99M -90.51M -35.06M -447M -34.26M -33.52M -1.44B
Net Debt	-10.68M -0 -3.5M -3.07M -2.9M -2.65M -4.95M -336M -4.99M -34.74M -13.46M -172M -13.15M -12.87M -551M	-20.14M -0 -6.61M -5.8M -5.48M -4.99M -9.34M -633M -9.41M -65.52M -25.38M -323M -24.8M -24.27M -1.04B